Virtual poster discussion session 1

28 April 2021

  • days
  • Hours
  • Minutes

Chair and moderators

Tim Lahm, Indiana University Medical Center, USA

Brian Graham, University of California, San Francisco, USA

Evangelos Michelakis, University of Alberta, Canada

Christophe Guignabert, Université Paris-Saclay, France

Anton Vonk Noordegraaf, Amsterdam University Medical Center, The Netherlands

Khodr Tello, Justus-Liebig University Giessen, Germany

Agenda

  • Iona Cuthbertson // Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin
  • Prakash Chelladurai // Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension
  • Charifa Awada // Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension
  • Barbora Kaftanová // Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats
  • Anandharajan Rathinasabapath // Endothelial overexpression of sirt3 protects the metabolic etiology in PAH
  • Tatyana Novoyatleva // Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension
  • Katherine Kearney Graham // Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry
  • Richard Channick // Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH)
  • Pietro Nardelli // Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects
  • Victor Tapson // Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease
  • Erik Swenson // Acetazolamide and high altitude pulmonary edema prevention
  • Manjula Miglani // Telomeric Tankyrases: a novel and propitious target to ameliorate the maladaptation phenomena at heights

Congratulations to Prakash Chelladurai, who has been awarded the Butrous Young Investigator Award 2020 for his abstract entitled: ‘epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension .’

A deeper look

In this first interactive poster discussion session, two rounds of presentations will cover basic and clinical science. Round 1 basic science presentations will be chaired by Dr Brian Graham (University of California, US), Dr Tim Lahm (Indiana University, US), and Dr Evangelos Michelakis (University of Alberta, Canada). In this session, we will learn about recent discoveries in pulmonary hypertension (PAH) field such as implication of new epigenetics regulators, metabolic dysfunction affecting vascular cells, new modulators of the BMPR2 axis, and the effect of serotonin inhibitor on PAH development in female rat. This session also includes the presentation from Prakash Chelladurai (Max-Plank-Institute for heart and lung research, Germany) entitled “Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension”, winner of the Butrous Youg Investigator award 2020 for his work on epigenomic profiling in pulmonary arterial hypertension.

The second round will be chaired by Dr Christophe Guignabert (Université Paris-Saclay, France), Dr Anton Vonk Noordegraaf (Amsterdam University, Netherlands) and Dr Khodr Tello (Justus-Liebig University, Germany). Poster presentations will provide novel insight on therapeutic approaches to prevent and improve effect of altitude on pulmonary vasculature and the use of artificial intelligence for contrast CT imaging classification of arteries and veins in PH patient. Other discussions will cover sub-cohort analysis of the INCREASE, GRIPHON and SERAPHIN clinical trials, and National Australian Registry, investigating the difference between age group and pulmonary hypertension types, highlighting the importance of considering these variables in patient management and in interpreting results of clinical studies.

 

ROUND ONE BASIC:

Poster 1: Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin

15:00-15:05 BST

Presenter: // Iona Cuthbertson, Department of Medicine, University of Cambridge, UK

 

Poster 2: Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension

15:10-15:15 BST

Presenter: // Prakash Chelladurai, Max-Planck-Institute for Heart And Lung Research, Germany

 

Poster 3: Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension

15:20-15:25 BST

Presenter: // Charifa Awada, the University Institute of Cardiology and Pulmonology of Quebec, Canada

 

Poster 4: Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats

15:30-15:35 BST

Presenter: // Barbora Kaftanová, Department of Physiology, Charles University Second Medical School, Czech Republic

 

Poster 5: Endothelial overexpression of sirt3 protects the metabolic etiology in PAH

15:40-15:45 BST

Presenter: // Anandharajan Rathinasabapathy, Vanderbilt University Medical Centre, USA

 

Poster 6: Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension

15:50-15:55 BST

Presenter: // Tatyana Novoyatleva, Justus-Liebig-University Giessen, Germany

 

ROUND TWO CLINICAL:

Poster 1: Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry

16:00-16:05 BST

Presenter: // Katherine Kearney Graham, University of New South Wales, Australia

 

Poster 2: Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH)

16:10-16:15 BST

Presenter: // Richard Channick, University of California Los Angeles Medical Centre, USA

 

Poster 3: Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects

16:20-16:25 BST

Presenter: // Pietro Nardelli, Brigham and Women's Hospital, Harvard Medical School, USA

 

Poster 4: Poster 4: Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease

16:30-16:35 BST

Presenter: // Victor Tapson, Cedars-Sinai Medical Centre, USA

 

Poster 5: Acetazolamide and high altitude pulmonary edema prevention

16:40-16:45 BST

Presenter: // Erik Swenson University of Washington, USA

 

Poster 6: Telomeric Tankyrases: A novel and propitious target to ameliorate the maladaptation phenomena at heights

16:50-16:55 BST

Presenter: // Manjula Miglani, SRM University, Haryana, India

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg